0A8D.L - Akers Biosciences, Inc.
| Previous close | 2.0580 |
| Open | 2.0800 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 2.0782 - 2.1312 |
| 52-week range | 1.1440 - 5.8693 |
| Volume | |
| Avg. volume | 3,275 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 15 Nov 2021 - 19 Nov 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireMyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan
BALTIMORE, MD, April 12, 2023--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, today announced a dosing update on its fully-funded Phase 2 clinical trial of lead drug candidate MYMD-1®, an orally available next-generation TNF-alpha inhibitor, as a therapy for chronic inflammation associated with sarcopenia and fra
Business WireMyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis
BALTIMORE, March 20, 2023--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, is presenting data from a preclinical study of investigational, oral TNF-α inhibitor MYMD-1® at the 2023 Society of Toxicology Annual Meeting (SOT) in Nashville, TN. Study results comparing MYMD-1 to placebo were very highly significant and
Business WireMyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls
BALTIMORE, March 08, 2023--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, today announced that it has joined LOT Network, the international, non-profit community of companies working together to protect themselves against litigation brought on by patent assertion entities (PAEs, also known as "patent trolls"). My
Business WireMyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical
BALTIMORE, March 02, 2023--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, today announced that the U.S. Drug Enforcement Administration (DEA) has conducted a scientific review and determined that investigational cannabinoid Supera-CBD™ is not currently considered a controlled substance or listed chemical. The sci
Business WireMyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting
BALTIMORE, February 28, 2023--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, announced that preclinical data from a study, conducted in partnership with Charles River Laboratories International, Inc., has been accepted for presentation at the upcoming Society of Toxicology (SOT) 2023 Annual Meeting.
Business WireMyMD Announces $15 Million Offering with Existing Investors
BALTIMORE, February 21, 2023--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, today announced that it has executed a securities purchase agreement to raise gross proceeds of approximately $15 million in a registered direct offering of convertible preferred stock and warrants with certain accredited and institution
Business WireADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022
BALTIMORE, December 06, 2022--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, is presenting data today at the 2022 British Society for Immunology (BSI) Congress in Liverpool, England. Results from preclinical and clinical studies showed that MYMD-1 was safe and well-tolerated in healthy subjects and significantly
Business WireMyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress
BALTIMORE, November 17, 2022--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, has been invited to present late-breaking data at the 2022 British Society for Immunology (BSI) Congress in Liverpool, England.
Business WireMyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research
BALTIMORE, November 14, 2022--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, today announced the publication of results from a Phase 1 study of oral tumor necrosis factor-alpha (TNF-α) inhibitor, MYMD-1® (Isomyosamine), in peer-reviewed journal, Drug Research. The randomized, double-blind, placebo-controlled study, intended to ev
Business WireMyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD™ Compound
BALTIMORE, August 30, 2022--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD"), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced today that it received a decision to grant from the European Patent Office in its application no. EP 3755318 A1. The allowed claims cover MyMD’s Supera-CBD™ compound as a new molecular entity and pharmaceutical formulations containing the compound.
Business WireData Showing MyMD Pharmaceuticals’ MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences
BALTIMORE, August 03, 2022--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced today the publication of data in the Journal of Gerontology: Biological Sciences (JGBS) from a pre-clinical study of MYMD-1® demonstrating four-fold greater improvements than rapamycin in delaying aging and extending the life of mice who began tr
Simply Wall St.Is MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) Popular Amongst Insiders?
A look at the shareholders of MyMD Pharmaceuticals, Inc. ( NASDAQ:MYMD ) can tell us which group is most powerful...
Business WireMyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan
BALTIMORE, July 26, 2022--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced further advancement of its fully funded Phase 2 clinical trial of lead drug candidate MYMD-1® as a therapy for delaying aging and expanding healthy lifespan. To date, the trial has completed dosing for the first patient cohort and dosing has been i
- Business Wire
MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions
BALTIMORE, July 12, 2022--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, announced today that it has entered into a material transfer agreement (MTA) with Bascom Palmer Eye Institute of Miami, Florida to collaborate on a pre-clinical study using MYMD-1® as a potential treatment for traumatic optic neuropathy (TON). The project is fully funded by Basco